Daily Cardiology Research Analysis
Analyzed 199 papers and selected 3 impactful papers.
Summary
Analyzed 199 papers and selected 3 impactful articles.
Selected Articles
1. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
In a multinational, double-blind RCT (n=2909), oral enlicitide lowered LDL-C by 57.1% at 24 weeks versus 3.0% with placebo, with sustained LDL-C reduction at 52 weeks and significant improvements in non-HDL-C, ApoB, and Lp(a). Adverse event rates were similar between groups, supporting a convenient, needle-free lipid-lowering option with large effect size.
Impact: First robust phase 3 evidence for an oral PCSK9 inhibitor achieving large, durable LDL-C reductions; could transform adherence and access compared with injectables.
Clinical Implications: Offers a potent, convenient alternative to injectable PCSK9 inhibitors that can facilitate broader uptake of intensive LDL-C lowering in secondary and high-risk primary prevention. Outcome trials remain needed for event reduction.
Key Findings
- LDL-C decreased by 57.1% at week 24 with enlicitide vs 3.0% increase with placebo (between-group −55.8 percentage points; P<0.001).
- Sustained LDL-C lowering through 52 weeks and significant improvements in non-HDL-C and ApoB at week 24 (P<0.001).
- Lipoprotein(a) also significantly reduced at week 24 (P<0.001) with similar adverse event rates between groups.
Methodological Strengths
- Multinational, double-blind, randomized, placebo-controlled design with large sample (n=2909).
- Prespecified lipid endpoints with consistent effects across multiple atherogenic lipoproteins.
Limitations
- Lipid surrogate endpoints; no cardiovascular outcomes yet.
- Follow-up limited to 52 weeks; long-term safety and adherence beyond 1 year are unknown.
Future Directions: Event-driven outcomes trials to establish cardiovascular benefit; head-to-head comparisons with injectable PCSK9 inhibitors and integration into cost-effectiveness frameworks.
BACKGROUND: Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. METHODS: In this multinational, double-blind, randomized, placebo-controlled trial, we enrolled adults with a history of a major atherosclerotic cardiovascular disease event with an LDL cholesterol level of 55 mg per deciliter or higher and those who were at risk for a first atherosclerotic cardiovascular disease event with an LDL cholesterol level of 70 mg per deciliter or higher. Participants were assigned in a 2:1 ratio to receive enlicitide at a dose of 20 mg or placebo daily for 52 weeks. The primary end point was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were the mean percent change in LDL cholesterol level at week 52 and the mean percent change in levels of non-high-density lipoprotein (non-HDL) cholesterol and apolipoprotein B and the percent change in lipoprotein(a) level at week 24. RESULTS: Of the 2909 participants in the intention-to-treat population, 1935 received enlicitide and 969 received placebo (5 did not receive enlicitide or placebo). The mean age of the participants was 63 years, and 39.3% were women. The mean (±SD) LDL cholesterol level at baseline was 96.1±38.9 mg per deciliter. The mean percent change in LDL cholesterol levels at week 24 was -57.1% (95% confidence interval [CI], -61.8 to -52.5) with enlicitide and 3.0% (95% CI, 0.9 to 5.1) with placebo, representing an adjusted between-group difference of -55.8 percentage points (95% CI, -60.9 to -50.7; P<0.001). The mean percent change in LDL cholesterol level at week 52, the mean percent changes in non-HDL cholesterol and apolipoprotein B levels at week 24, and the percent change in lipoprotein(a) levels at week 24 were significantly greater with enlicitide than with placebo (P<0.001 for all comparisons). The incidence of adverse events did not appear to differ between the groups. CONCLUSIONS: Among participants who had a history of or were at risk for a first atherosclerotic cardiovascular disease event, treatment with the oral PCSK9 inhibitor enlicitide resulted in significantly lower LDL cholesterol levels than placebo at 24 weeks. (Funded by MSD [Rahway, NJ]; CORALreef Lipids ClinicalTrials.gov number, NCT05952856.).
2. Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
In asymptomatic patients with very severe aortic stenosis (n=145), early surgery reduced the 10-year cumulative incidence of operative mortality or cardiovascular death to 1% vs 19% with conservative care (HR 0.10). All-cause mortality was also lower with early surgery (15% vs 32%; HR 0.42), supporting proactive intervention.
Impact: Provides long-term randomized evidence that early surgery improves survival in asymptomatic very severe aortic stenosis, informing timing of aortic valve intervention.
Clinical Implications: Supports considering early surgical aortic valve replacement in asymptomatic very severe stenosis to reduce long-term cardiovascular and all-cause mortality, with shared decision-making and surgical risk assessment.
Key Findings
- Primary endpoint (operative mortality or cardiovascular death) at 10 years: 1% early surgery vs 19% conservative care (HR 0.10; 95% CI 0.02–0.43; P=0.002).
- All-cause mortality: 15% early surgery vs 32% conservative care (HR 0.42; 95% CI 0.21–0.86).
- Benefits observed in intention-to-treat analysis, reinforcing robustness despite modest sample size.
Methodological Strengths
- Randomized, intention-to-treat analysis with 10-year follow-up.
- Clinically hard endpoints (cardiovascular and all-cause mortality).
Limitations
- Modest sample size (n=145) and conducted in a specific healthcare setting, which may limit generalizability.
- Evolving surgical and transcatheter techniques over a decade could influence applicability.
Future Directions: Comparative trials and registries integrating contemporary SAVR vs TAVR in asymptomatic very severe AS, with quality-of-life and cost-effectiveness endpoints.
BACKGROUND: Among asymptomatic patients with severe aortic stenosis, a previous analysis showed that the risk of a composite of death during surgery or within 30 days after surgery (called operative mortality) or death from cardiovascular causes was significantly lower with early surgery than with conservative care. However, the long-term survival benefit of early surgery, as compared with conservative care, remains unclear. METHODS: We randomly assigned asymptomatic patients with very severe aortic stenosis (defined as an aortic-valve area of ≤0.75 cm RESULTS: A total of 145 patients underwent randomization. In an intention-to-treat analysis, a primary end-point event occurred in 2 of 73 patients (3%) in the early-surgery group and in 17 of 72 (24%) in the conservative-care group (hazard ratio, 0.10; 95% confidence interval [CI], 0.02 to 0.43; P = 0.002). At 10 years, the cumulative incidence of operative mortality or death from cardiovascular causes was 1% in the early-surgery group and 19% in the conservative-care group. Death from any cause occurred in 11 patients (15%) in the early-surgery group and in 23 (32%) in the conservative-care group (hazard ratio, 0.42; 95% CI, 0.21 to 0.86). CONCLUSIONS: Among asymptomatic patients with very severe aortic stenosis, early surgery led to a lower risk of a composite of operative mortality or death from cardiovascular causes than conservative care at 10 years. (Funded by the Korean Institute of Medicine; RECOVERY ClinicalTrials.gov number, NCT01161732.).
3. Cardiomyocyte Cyclin-dependent kinase 9 directly binds to and phosphorylates NF-κB p65 subunit to drive cardiac inflammation and remodeling.
This mechanistic study shows that CDK9 directly binds to and phosphorylates NF-κB p65 in cardiomyocytes, driving inflammation and hypertrophic remodeling independently of IKKβ and RNAPII pathways. Genetic and pharmacologic inhibition of CDK9 signaling attenuated Ang II–induced cardiac inflammation, remodeling, and dysfunction in mice, nominating CDK9 as a therapeutic target in heart failure.
Impact: Identifies a cell cycle–independent, druggable kinase–transcription factor axis (CDK9–p65) as a core driver of cardiac inflammation and remodeling with in vivo rescue by pharmacologic inhibition.
Clinical Implications: CDK9 phosphorylation (Thr-186) and the CDK9–p65 interaction could serve as biomarkers and therapeutic targets. Development of selective CDK9 inhibitors and translational studies in human heart failure may yield anti-inflammatory, anti-remodeling therapies.
Key Findings
- CDK9 Thr-186 phosphorylation is increased in human and mouse hypertrophic hearts.
- Cardiomyocyte CDK9 T186A loss-of-function blunts Ang II–induced remodeling and NF-κB–mediated inflammation; T186E overactivation promotes them.
- CDK9 directly binds and phosphorylates NF-κB p65, enabling nuclear translocation and inflammatory/hypertrophic gene transcription independently of IKKβ and RNAPII pathways and requiring Cyclin T1.
- Pharmacological inhibition of CDK9 phosphorylation mitigates cardiac inflammation, remodeling, and dysfunction in mice.
Methodological Strengths
- Convergent multi-system evidence: human tissue, mouse models, and cardiomyocyte-targeted genetic mutants (T186A/T186E).
- Mechanistic specificity with direct CDK9–p65 binding, pathway dissection (IKKβ- and RNAPII-independent), and pharmacologic rescue.
Limitations
- Preclinical study without human interventional validation.
- Potential off-target effects and long-term safety of CDK9 inhibition remain uncharacterized.
Future Directions: Develop selective CDK9 inhibitors, evaluate efficacy and safety in large-animal heart failure models, and pursue biomarker-guided early-phase clinical trials targeting the CDK9–p65 axis.
Hypertensive heart failure highlights an urgent need for effective therapeutic strategies. Protein kinases regulate multiple pathways in cardiac pathophysiology and may provide promising therapeutic targets. Here, we identified a Cyclin-dependent kinase, CDK9, promoting inflammation and cardiac remodeling in terminally differentiated cardiomyocytes. Firstly, kinase enrichment analysis and experimental evidence revealed CDK9 phosphorylation at Thr-186 in both human and mouse hypertrophic heart tissues. CDK9 loss of function via T186A mutation in cardiomyocytes attenuated Ang II-induced heart remodeling and NF-κB-mediated inflammation, whereas CDK9 overactivation by T186E mutation induces. This regulatory function of CDK9 in cardiac remodeling is cell cycle-independent. Further studies demonstrate that the kinase domain of CDK9 directly binds to NF-κB P65 protein, which leads to the CDK9/P65 complex nuclear translocation, P65 phosphorylation, and transcription of inflammatory and hypertrophic genes in cardiomyocytes. This process requires CDK9 Thr-186 phosphorylation and Cyclin T1 presence, but is independent on IKKβ and CDK9-RNAPII pathways. Pharmacological inhibition of CDK9 phosphorylation significantly attenuated Ang II-induced cardiac inflammation, remodeling, and dysfunction in mice. Collectively, Ang II-activated CDK9 directly binds to and phosphorylates P65 to drive cardiac inflammation and remodeling. This study identifies CDK9 as a potential target in heart failure therapeutics.